It’s the eve of the election, and a lot is at stake for investors.
From tech regulation, to taxes and energy policy, there’s a ton riding on the outcome.
We’ll follow everything you need to know – including the record money pouring into campaigns, and all the possible outcomes for stocks in the coming days.
Plus, our own Meg Tirrell explains why Regeneron’s promising COVID-19 antibody treatment would be in shortsupply if the FDA approved it today.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
